The bill seeks to amend the General Laws to protect patient choice in the dispensing of clinician-administered drugs, which are defined as outpatient infused prescription drugs that are not self-administered and are typically given in a clinical setting. It requires health insurers or their third parties to authorize, approve, and pay for such drugs when administered by an in-network hospital or clinic, in accordance with the provider contract and the insurer's medical and payment policies. The bill also mandates that reimbursement rates for these drugs be negotiated at rates equal to those paid to preferred pharmacies.

Additionally, the bill tasks the office of the health insurance commissioner with conducting an analysis of the payment process for clinician-administered drugs after January 1, 2025. This analysis will include data on payment accuracy and reimbursement calculations, and the findings will be summarized and published without identifying specific insurers or providers. Legislative recommendations to improve the reimbursement process, considering the potential costs to various stakeholders, will be provided to the general assembly by February 28, 2026. The bill aims to ensure that patients can choose where to receive their clinician-administered drugs without incurring additional costs or penalties, and it is set to take effect on January 1, 2025.